GT Biopharma Statistics
Total Valuation
GT Biopharma has a market cap or net worth of $4.96 million. The enterprise value is -$8.87 million.
| Market Cap | 4.96M |
| Enterprise Value | -8.87M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GT Biopharma has 1.38 million shares outstanding. The number of shares has increased by 26.87% in one year.
| Shares Outstanding | 1.38M |
| Shares Change (YoY) | +26.87% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 10.42% |
| Owned by Institutions (%) | 13.46% |
| Float | 1.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.67 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.12 |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34.67 |
Financial Efficiency
Return on equity (ROE) is -71.80% and return on invested capital (ROIC) is -180.20%.
| Return on Equity (ROE) | -71.80% |
| Return on Assets (ROA) | -44.40% |
| Return on Capital (ROIC) | -180.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.80M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.05% in the last 52 weeks. The beta is 0.57, so GT Biopharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.57 |
| 52-Week Price Change | -63.05% |
| 50-Day Moving Average | 4.20 |
| 200-Day Moving Average | 6.63 |
| Relative Strength Index (RSI) | 45.62 |
| Average Volume (30 Days) | 13,604 |
Short Selling Information
The latest short interest is 8,746, so 0.63% of the outstanding shares have been sold short.
| Short Interest | 8,746 |
| Short Previous Month | 4,898 |
| Short % of Shares Out | 0.63% |
| Short % of Float | 0.75% |
| Short Ratio (days to cover) | 0.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.58M |
| Pretax Income | -7.60M |
| Net Income | -7.60M |
| EBITDA | -7.38M |
| EBIT | -7.38M |
| Earnings Per Share (EPS) | -$5.64 |
Balance Sheet
The company has $13.97 million in cash and $58,000 in debt, giving a net cash position of $13.91 million or $10.08 per share.
| Cash & Cash Equivalents | 13.97M |
| Total Debt | 58,000 |
| Net Cash | 13.91M |
| Net Cash Per Share | $10.08 |
| Equity / Book Value | 7.48M |
| Book Value Per Share | 5.41 |
| Working Capital | 7.42M |
Cash Flow
| Operating Cash Flow | -8.85M |
| Capital Expenditures | n/a |
| Free Cash Flow | -8.85M |
| FCF Per Share | -$6.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GT Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.87% |
| Shareholder Yield | -26.87% |
| Earnings Yield | -150.76% |
| FCF Yield | -175.66% |
Analyst Forecast
The average price target for GT Biopharma is $105.00, which is 2,801.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $105.00 |
| Price Target Difference | 2,801.35% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 5, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Feb 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |